Yondelis for liposarcoma. pro
Long-term follow-up of a large study showed that trabectedin (Yondelis) was associated with high rates of survival and clinical benefit rate for patients with advanced high-grade soft tissue sarcomas, especially liposarcoma and leiomyosarcoma. There are a number of smaller studies confirming that it is ane effective drug. In 2015, the U.S. Food and Drug Administration approved the use of trabectedin for the treatment of unresectable or metastatic LPS and LMS.
Recine F, Bongiovanni A, Riva N, et al. Update on the role of trabectedin in the treatment of intractable soft tissue sarcomas. Onco Targets Ther. 2017;10:11551164.
Demetri GD, Chawla SP, von Mehren M, et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol. 2009;27(25):41884196.
De Sanctis R, Marrari A, Marchetti S, et al. Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma. Drug Des Devel Ther. 2015;27(9):57855791
Yondelis, Prescribing Information 2019